Pyxis Oncology, Inc.

NASDAQ:PYXS

Biotechnology

Healthcare
$1.44 +5.53%

+$0.11 today

Market cap
$172.24M
Beta
1.43
P/E (TTM)
-1.6
EPS (TTM)
-$1.29
52W Low $0.97High $5.55

Volume 1.44M

Average 0.50M

Returns on capital

Pyxis Oncology, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-149.1%

avg -28.2%

ROIC

-117.1%

avg -75.2%

ROA

-87.0%

avg -57.6%

Analysis

ROA is currently the strongest return metric at -87.0% versus its period average of -57.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jitendra Wadhane

Chief Accounting Officer, Senior Vice President of Finance, Corporate Controller & Principal Financial OfficerUSD 559.05K46262.63K0.41%

Thomas Civik

CEO & ChairmanUSD 47.5K572.50M3.95%

Stan Szpindor

Head of R&D Quality————

Shui He

Head of Biometrics————

Donna Regalado

Head of Human Resources————

Balu N. Balasubramanian

Interim Chief Technology Officer————

Charles T. Gombar

Senior Vice President of Portfolio & Program Management————

Hongwei Wang

Head of ADC Development & Clinical Strategy————

Marsha Crochiere

Head of Translational Medicine & Research————

Michael Bui

Senior Vice President of Global Regulatory Affairs————

Supriya Roth

Head of Commercial Development————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 4, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

3

$51.52M

Sells

1

$107,100.00

Net Transaction Value

+$51.41M

Net buying

Most Active

GordonMD Global Investments LP

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 1, 26

GordonMD Global Investments LP

Indirect

Buy$25.1M
Oct 1, 26

GordonMD Global Investments LP

Indirect

Buy$0
Oct 1, 26

GordonMD Global Investments LP

Indirect

Buy$26.4M
Jun 30, 26

Dupont Jakob

Direct

Sell$107.1K

Summary

Insiders reported 3 buys worth $51.52M and 1 sells worth $107,100.00 over the last 12 months. That adds up to net buying of $51.41M. GordonMD Global Investments LP was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
+54.6% (5yr)4 analysts
Net IncomeN/AN/AN/A
N/A4 analysts
EBITN/AN/AN/A
N/A4 analysts

Analysis

Forward estimates point to Revenue at +54.6% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Pyxis Oncology, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about PYXS's management, answered from reported figures.

Who manages PYXS?

Pyxis Oncology, Inc. (PYXS) lists 11 active executives. The top listed executive is Stan Szpindor, Head of R&D Quality.

Are PYXS insiders buying or selling?

Recent insider activity shows net buying of $111.29M.